The company's second asset showed activity against ... Acurx seeks non-dilutive funding from government programs like BARDA, Project BioShield, and potential partnerships to support Phase 3 ...

Research & Development Revenue for Q3 2024 rose 138% to $8.2 million from $3.4 million, primarily reflecting an increased ...

Past ThinkEquity conferences have featured over 70 company presentations ... that would provide additional funding for the Project BioShield program. In addition, there can be no assurance ...

Soligenix is a late-stage biopharmaceutical company focused on developing and ... that would provide additional funding for the Project BioShield program. In addition, there can be no assurance ...

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Soligenix is a late-stage biopharmaceutical company focused on developing and ... that would provide additional funding for the Project BioShield program. In addition, there can be no assurance ...

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis ...

Members of Soligenix management will also be holding one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule on-on-one meetings here. Soligenix is a ...

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics ...